Health
Pfizer/BioNTech COVID-19 vaccine continues to show strong effect in early-stage study – Seeking Alpha
Data from an ongoing Phase 1/2 clinical trial evaluating three dose levels of Pfizer (NYSE:PFE) and collaboration partner BioNTech SE’s (NASDAQ:BNTX) COVID-19 vaccine candidate BNT162b1 in healthy volunteers showed an acceptable safety profile and dose-depend…
Data from an ongoing Phase 1/2 clinical trial evaluating three dose levels of Pfizer (NYSE:PFE) and collaboration partner BioNTech SE’s (NASDAQ:BNTX) COVID-19 vaccine candidate BNT162b1 in healthy volunteers showed an acceptable safety profile and dose-dependent increases in glycoprotein receptor-binding domain (RBD)-binding IgG concentrations and SARS-CoV-2 neutralizing antibody titers. The data, just published in the journal Nature, was generated on the first two dose levels, 10 µg and 30 µg. …
-
Noosa News13 hours agoMan dies in Brisbane crash, women and girl rushed to hospital
-
General22 hours agoProductivity summit ends day two with progress on rules changes to boost housing supply
-
Noosa News19 hours agoChilling new details emerge in terrifying childcare centre incident in Peregian Springs on the Sunshine Coast
-
Noosa News19 hours agoThe key industries on the rise as Brisbane economy hits $200b